Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$57.33 - $68.61 $1.36 Million - $1.63 Million
-23,800 Reduced 14.31%
142,500 $9.42 Million
Q2 2024

Aug 14, 2024

BUY
$51.18 - $63.75 $2.11 Million - $2.63 Million
41,200 Added 32.93%
166,300 $10.1 Million
Q1 2024

May 15, 2024

BUY
$56.55 - $66.59 $4.01 Million - $4.72 Million
70,900 Added 130.81%
125,100 $7.13 Million
Q4 2023

Feb 14, 2024

BUY
$52.16 - $64.19 $125,183 - $154,056
2,400 Added 4.63%
54,200 $3.4 Million
Q3 2023

Nov 14, 2023

SELL
$57.77 - $65.93 $4.75 Million - $5.42 Million
-82,200 Reduced 61.34%
51,800 $2.99 Million
Q2 2023

Aug 14, 2023

BUY
$60.95 - $75.51 $6.37 Million - $7.89 Million
104,500 Added 354.24%
134,000 $8.34 Million
Q1 2023

May 15, 2023

SELL
$70.23 - $86.01 $1.94 Million - $2.37 Million
-27,600 Reduced 48.34%
29,500 $2.13 Million
Q4 2022

Feb 14, 2023

BUY
$67.18 - $84.11 $275,438 - $344,851
4,100 Added 7.74%
57,100 $4.59 Million
Q3 2022

Nov 14, 2022

SELL
$66.18 - $82.86 $1.21 Million - $1.52 Million
-18,300 Reduced 25.67%
53,000 $3.53 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.6B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.